Targeted therapy monitoring of BRAF-V600-mutant Erdheim-Chester disease by fast quantitative whole-body bone CZT-tomoscintigraphies

Erdheim-Chester disease (ECD) is a rare histiocytosis due to proto-oncogene mutations, primarily affecting the long bones and possibly being treated by novel targeted therapies. (18)F-FDG PET is a reference technique for ECD assessment. However, we present a case where easier and more objective moni...

Descripción completa

Detalles Bibliográficos
Autores principales: Melki, Saifeddine, Moulinet, Thomas, Verger, Antoine, Marie, Pierre-Yves, Imbert, Laetitia, Bahloul, Achraf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837338/
https://www.ncbi.nlm.nih.gov/pubmed/36635469
http://dx.doi.org/10.1186/s41824-022-00160-3
Descripción
Sumario:Erdheim-Chester disease (ECD) is a rare histiocytosis due to proto-oncogene mutations, primarily affecting the long bones and possibly being treated by novel targeted therapies. (18)F-FDG PET is a reference technique for ECD assessment. However, we present a case where easier and more objective monitoring of the ECD-related bone metabolism abnormalities under treatment was obtained with the standardized uptake value-based information provided by fast whole-body [Tc-99 m]-HDP bone tomoscintigraphies (QWBT) recorded with a high-sensitivity CZT-camera/computed tomography (CT) hybrid system. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41824-022-00160-3.

Ejemplares similares